Evidence map›Paper›PMID 41965354›Full record

ArticleNature communications2026

A synthetic angiotensin II/ACE2-based hormone shunt controlling experimental hypertension.

Gokberk Unal, Maysam Mansouri, Yu-Qing Xie, Christian Mueller, Ghislaine Charpin-El Hamri, Martin Fussenegger

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Gokberk UnalDepartment of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.
Maysam MansouriDepartment of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.ORCID http://orcid.org/0000-0001-7396-2372
Yu-Qing XieDepartment of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.
Christian MuellerDepartment of Cardiology, University Hospital Basel, Basel, Switzerland.ORCID http://orcid.org/0000-0002-1120-6405
Ghislaine Charpin-El HamriDepartment of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.
Martin FusseneggerDepartment of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland. fussenegger@bsse.ethz.ch.ORCID http://orcid.org/0000-0001-8545-667X

Funding

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) NCCR Molecular Systems Engineering
6 · The paper itself

Abstract

Arterial hypertension is the leading preventable cause of various life-threatening medical conditions and comorbidities that affect over 1.3 billion adults, causing over 7.5 million annual deaths worldwide. Capitalizing on a synthetic biology-inspired engineering approach, we design a fully human, antihypertensive gene circuit called ARCH (autonomous regulator of chronic hypertension), which precisely monitors and efficiently controls angiotensin-dependent, renin-angiotensin system (RAS)-driven hypertension, in which angiotensin II (Ang-II) is persistently elevated, in a reversible, self-sufficient, and closed-loop manner. We utilize the ectopically expressed native type-1 angiotensin receptor (AT

Indexed as

Angiotensin-Converting Enzyme 2Angiotensin IIHypertensionPeptidyl-Dipeptidase AAnimalsBlood PressureDisease Models, AnimalHumansMaleMicePromoter Regions, GeneticReceptor, Angiotensin, Type 1Renin-Angiotensin SystemACE2 protein, humanAngiotensin-Converting Enzyme 2Angiotensin IIPeptidyl-Dipeptidase AReceptor, Angiotensin, Type 1

Identifiers

PMID41965354
PMCPMC13247273

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.